Vpr Gene Linked to HIV Immune Dysfunction

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 11
Volume 4
Issue 11

LOS ANGELES-Researchers at the AIDS Institute of UCLA have identified an HIV gene that appears to play a role in HIV immunosuppression by inhibiting reproduction of CD4+ T cells

LOS ANGELES-Researchers at the AIDS Institute of UCLA have identifiedan HIV gene that appears to play a role in HIV immunosuppressionby inhibiting reproduction of CD4+ T cells.

The Vpr gene expresses a protein that prevents infected T cellsfrom progressing normally through the cell cycle. Cell growthstops in the G2 phase or early in mitosis. The research showedthat expression of the Vpr gene protein is necessary and sufficientto cause the arrest (Journal of Virology 69:6304-6313, 1995).

Study investigator Jeremy B.M. Jowett, PhD, said in an interviewthat more recent data suggest that these cells probably eventuallyundergo apoptosis, thus implicating the Vpr gene in the ultimatedrastic reduction in CD4 cells seen in late-stage HIV infection.

This model for HIV-induced immune dysfunction opens up possiblenew avenues of therapy. "At this stage, we don't know howthe protein acts," Dr. Jowett said. "It could be bindingto another protein or turning on other genes, acting as a transcriptionenhancer. Once we understand it, we can try to block it, perhapsby blocking receptors or by antisense RNA techniques to inhibittranscription."

Importance to Cancer Research

These findings could also be important in cancer research. Inlaboratory experiments, he said, the Vpr protein arrested thegrowth of HeLa human cervical cancer cells, which led to celldeath. Dr. Jowett's lab has also shown that the Vpr protein canarrest the growth of p53-deficient retinoblastoma cells.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content